Drug Profile
Recombinant influenza virus vector carrier vaccine (HIV) - Polymun Scientific
Alternative Names: influenza A virus vector carrier vaccine (HIV) - Polymun ScientificLatest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator Polymun Scientific
- Class AIDS vaccines; Attenuated vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - HIV infections
Highest Development Phases
- Preclinical HIV infections
Most Recent Events
- 01 Sep 2023 Recombinant influenza virus vector carrier vaccine (HIV) is still in preclinical phase for HIV-infections (Prevention) in Austria (Intranasal, Spray) (Polymun Scientific Website; September 2023)
- 22 Apr 2016 Preclinical trials in HIV infections (Prevention) in Austria (Intranasal)